Bone Therapeutics Invests in Cell Therapy Manufacturing Facility Read more about Bone Therapeutics Invests in Cell Therapy Manufacturing Facility
Bone Therapeutics Awarded Manufacturing Authorisation and European Approval to Produce Allogeneic Bone Cell Therapy Products Read more about Bone Therapeutics Awarded Manufacturing Authorisation and European Approval to Produce Allogeneic Bone Cell Therapy Products
Bone Therapeutics to Present at Upcoming Investor Conferences Read more about Bone Therapeutics to Present at Upcoming Investor Conferences
Bone Therapeutics and Erasme University Start Phase IIa Trial in Osteoporosis with its Cell Therapy Product PREOB® Read more about Bone Therapeutics and Erasme University Start Phase IIa Trial in Osteoporosis with its Cell Therapy Product PREOB®
Fondation de la Plateforme Wallonne de Thérapie Cellulaire: La plateforme vise à produire les médicaments de thérapie cellulaire à grande échelle Read more about Fondation de la Plateforme Wallonne de Thérapie Cellulaire: La plateforme vise à produire les médicaments de thérapie cellulaire à grande échelle
Bone Therapeutics Appoints Wim Goemaere as Chief Financial Officer Read more about Bone Therapeutics Appoints Wim Goemaere as Chief Financial Officer
Bone Therapeutics receives clearance for ALLOB® phase I/IIa trial Read more about Bone Therapeutics receives clearance for ALLOB® phase I/IIa trial
Bone Therapeutics treats first patients in PREOB® pivotal phase IIb/III trial for the treatment of non-union fractures Read more about Bone Therapeutics treats first patients in PREOB® pivotal phase IIb/III trial for the treatment of non-union fractures
Bone Therapeutics’ pivotal phase III osteonecrosis trial with PREOB® hits a new milestone - 30 centres across Europe now active Read more about Bone Therapeutics’ pivotal phase III osteonecrosis trial with PREOB® hits a new milestone - 30 centres across Europe now active
Bone Therapeutics and partners awarded highly competitive €3.8 million Marie Curie research grant Read more about Bone Therapeutics and partners awarded highly competitive €3.8 million Marie Curie research grant
